{"id":"sox-or-capox-regimen","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and repair. Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis.","oneSentence":"Oxaliplatin and capecitabine work by interfering with DNA replication and repair, thereby inhibiting cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:34.492Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":"Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT","enrollment":9},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07098949","phase":"NA","title":"Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08","conditions":"Gastric Cancer","enrollment":346},{"nctId":"NCT07068516","phase":"PHASE3","title":"Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2025-07-20","conditions":"Gastric Cancer Stage","enrollment":470},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SOX or CAPOX regimen","genericName":"SOX or CAPOX regimen","companyName":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","companyId":"daping-hospital-and-the-research-institute-of-surgery-of-the-third-military-medi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The SOX regimen, which includes Pembrolizumab, is used to treat various types of cancer, including Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Gastric (Stomach) Cancer, and Gastric Adenocarcinoma. The regimen may also include Cisplatin, a chemotherapy medication, and is compared to a placebo in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}